ERBB2 and breast cancer: The EMILIA study was a phase III, randomized, multicenter, open-label trial of ado-trastuzumab emtansine vs.capecitabine plus lapatinib in 991 women with metastatic HER2-positive breast cancer who progressed on or within 6months of having received trastuzumab and who had received taxane chemotherapy (Verma et al., 2012).